Connect Biopharma Holdings (CNTB) EBT (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported EBT for 3 consecutive years, with -$19.3 million the latest figure, recorded in Q1 2026.

• Quarterly EBT fell 89.37% year-over-year to -$19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.4 million (down 279.81% YoY) and the FY2025 annual result came in at -$55.3 million, down 258.86% from the prior year.
• EBT declined to -$19.3 million in Q1 2026 per CNTB's latest filing, from -$15.1 million in the prior quarter.
• Over the last five years, EBT for CNTB reached as high as $14.9 million in Q2 2024 and fell as low as -$19.3 million in Q1 2026.
• A 3-year average of -$10.0 million and a median of -$12.8 million in 2024 frame the typical range for EBT.
• The largest YoY upside for EBT was 17.95% in 2025 against a maximum downside of 186.33% in 2025.
• Year by year, EBT stood at -$8.8 million in 2024, then slumped by 71.39% to -$15.1 million in 2025, then fell by 28.3% to -$19.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$19.3 million, -$15.1 million, and -$17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.